Statin Intolerance: Diagnosis and Remedies

Angela Pirillo, Alberico Luigi Catapano

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, lipophilicity, and type of metabolism), and the concomitant administration of other drugs. Thus, the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, involves alternative therapies, including the switch to another statin or the use of intermittent dosage statin regimens, as well as nonstatin lipid lowering drugs (ezetimibe and fibrates) or new hypolipidemic drugs such as PCSK9 monoclonal antibodies, the antisense oligonucleotide against the coding region of human apolipoprotein B mRNA (mipomersen), and microsomal triglyceride transfer protein inhibitor lomitapide. Ongoing clinical trials will reveal whether the lipid-lowering effects of alternative therapies to statins can also translate into a cardiovascular benefit.

Original languageEnglish
JournalCurrent Cardiology Reports
Volume17
Issue number5
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Complementary Therapies
Lipids
Hypolipidemic Agents
Fibric Acids
Sex Factors
Antisense Oligonucleotides
Age Factors
Apolipoproteins B
Primary Prevention
Secondary Prevention
Pharmaceutical Preparations
Monoclonal Antibodies
Clinical Trials
Messenger RNA

Keywords

  • Myalgia
  • Myopathy
  • Statin intolerance
  • Statins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Statin Intolerance : Diagnosis and Remedies. / Pirillo, Angela; Catapano, Alberico Luigi.

In: Current Cardiology Reports, Vol. 17, No. 5, 01.05.2015.

Research output: Contribution to journalArticle

@article{effdf4949c5d4733bcedc04d78d0c726,
title = "Statin Intolerance: Diagnosis and Remedies",
abstract = "Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, lipophilicity, and type of metabolism), and the concomitant administration of other drugs. Thus, the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, involves alternative therapies, including the switch to another statin or the use of intermittent dosage statin regimens, as well as nonstatin lipid lowering drugs (ezetimibe and fibrates) or new hypolipidemic drugs such as PCSK9 monoclonal antibodies, the antisense oligonucleotide against the coding region of human apolipoprotein B mRNA (mipomersen), and microsomal triglyceride transfer protein inhibitor lomitapide. Ongoing clinical trials will reveal whether the lipid-lowering effects of alternative therapies to statins can also translate into a cardiovascular benefit.",
keywords = "Myalgia, Myopathy, Statin intolerance, Statins",
author = "Angela Pirillo and Catapano, {Alberico Luigi}",
year = "2015",
month = "5",
day = "1",
doi = "10.1007/s11886-015-0582-z",
language = "English",
volume = "17",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Statin Intolerance

T2 - Diagnosis and Remedies

AU - Pirillo, Angela

AU - Catapano, Alberico Luigi

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, lipophilicity, and type of metabolism), and the concomitant administration of other drugs. Thus, the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, involves alternative therapies, including the switch to another statin or the use of intermittent dosage statin regimens, as well as nonstatin lipid lowering drugs (ezetimibe and fibrates) or new hypolipidemic drugs such as PCSK9 monoclonal antibodies, the antisense oligonucleotide against the coding region of human apolipoprotein B mRNA (mipomersen), and microsomal triglyceride transfer protein inhibitor lomitapide. Ongoing clinical trials will reveal whether the lipid-lowering effects of alternative therapies to statins can also translate into a cardiovascular benefit.

AB - Despite the efficacy of statins in reducing cardiovascular events in both primary and secondary prevention, the adherence to statin therapy is not optimal, mainly due to the occurrence of muscular adverse effects. Several risk factors may concur to the development of statin-induced myotoxicity, including patient-related factors (age, sex, and race), statin properties (dose, lipophilicity, and type of metabolism), and the concomitant administration of other drugs. Thus, the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, involves alternative therapies, including the switch to another statin or the use of intermittent dosage statin regimens, as well as nonstatin lipid lowering drugs (ezetimibe and fibrates) or new hypolipidemic drugs such as PCSK9 monoclonal antibodies, the antisense oligonucleotide against the coding region of human apolipoprotein B mRNA (mipomersen), and microsomal triglyceride transfer protein inhibitor lomitapide. Ongoing clinical trials will reveal whether the lipid-lowering effects of alternative therapies to statins can also translate into a cardiovascular benefit.

KW - Myalgia

KW - Myopathy

KW - Statin intolerance

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84928322089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928322089&partnerID=8YFLogxK

U2 - 10.1007/s11886-015-0582-z

DO - 10.1007/s11886-015-0582-z

M3 - Article

C2 - 25894795

AN - SCOPUS:84928322089

VL - 17

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 5

ER -